Head-To-Head Analysis: InspireMD (NSPR) and Its Peers

InspireMD (NYSE:NSPR) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its competitors? We will compare InspireMD to related companies based on the strength of its analyst recommendations, dividends, profitability, valuation, institutional ownership, risk and earnings.

Profitability

This table compares InspireMD and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InspireMD	-413.96%	-69.42%	-57.68%
InspireMD Competitors	-367.60%	-172.56%	-24.30%

Volatility and Risk

InspireMD has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, InspireMD’s competitors have a beta of 1.25, suggesting that their average stock price is 25% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for InspireMD and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0	0	3	0	3.00
InspireMD Competitors	4240	10435	18125	818	2.46

InspireMD currently has a consensus target price of $4.50, indicating a potential upside of 889.01%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 24.85%. Given InspireMD’s stronger consensus rating and higher possible upside, analysts clearly believe InspireMD is more favorable than its competitors.

Institutional and Insider Ownership

44.8% of InspireMD shares are owned by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 25.0% of InspireMD shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares InspireMD and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
InspireMD	$10.84 million	-$19.92 million	-0.71
InspireMD Competitors	$840.40 million	$55.25 million	11.29

InspireMD’s competitors have higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

InspireMD competitors beat InspireMD on 7 of the 13 factors compared.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.